Hematologic manifestations and impaired liver synthetic function during valproate monotherapy

Brain and Development

Volumn 18, Issue 2, 1996, Pages 105-109

  Hauser, Erwin ^a   Seidl, Rainer ^a   Freilinger, Michael ^a   Male, Christoph ^a   Herkner, Kurt ^b  

^a UNIVERSITY OF VIENNA   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

Author keywords

Albumin; Anticonvulsants; Fibrinogen; Protein; Valproate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ANTICONVULSIVE AGENT; ASPARTATE AMINOTRANSFERASE; CYANOCOBALAMIN; FIBRINOGEN; FOLIC ACID; GAMMA GLUTAMYLTRANSFERASE; PLASMA PROTEIN; VALPROIC ACID;

ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CELL COUNT; BLOOD CLOTTING; CHILD; CLINICAL ARTICLE; EPILEPSY; ERYTHROCYTE COUNT; FIBRINOGEN BLOOD LEVEL; FOLIC ACID BLOOD LEVEL; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEMATOPOIETIC STEM CELL; HUMAN; LIVER FUNCTION; LIVER TOXICITY; MEAN CORPUSCULAR VOLUME; SCREENING; STEM CELL; THROMBIN TIME; THROMBOCYTE COUNT; VITAMIN BLOOD LEVEL;

EID: 0029917559     PISSN: 03877604     EISSN: None     Source Type: Journal    
DOI: 10.1016/0387-7604(95)00139-5     Document Type: Article

References (20)

1. Dreifuss FE, Santilli RN, Langer DH, Sweeney KP, Moline KA, Menander KB. Valproic acid hepatic facilities: A retrospective review. Neurology 1987; 37: 379-85.
2. Dreifuss FE, Langer DH, Moline KA, Maxwell JE. Valproic acid fatalities. II. U.S. experience since 1984. Neurology 1988; 39: 201-7.
3. Scheffner D, Koenig S, Rauterberg-Ruland L, Kochen W, Hoffmann WJ, Unkelbach S. Fatal liver failure in 16 children with valproate therapy. Epilepsia 1988; 29: 530-42.
4. Zimmerman NJ, Ishak KG. Valproate-induced injury: analysis of 23 fatal cases. Hepatology 1982; 2: 591-7.
5. Zafrani ES, Berthelot P. Sodium valproate in the induction of unusual hepatotoxicity. Hepatology 1982; 2: 648-9.
6. Loyning Y, Johannessen SL, Ritland S, Standjord RE, Kloster R. Cases of serious/fatal hepatotoxicity due to valproate: recommended monitoring scheme and preliminary results. In: Oxley J, Janz D, Meinardi H, eds. Chronic toxicity of antiepileptic drugs. New York: Raven Press, 1982; 47-60.
7. Jeavons PM. Non-dose-related side effects of valproate. Epilepsia 1984; 25 (suppl 1): 50-5.
8. Powell-Jackson PR, Tredger JM, Williams R. Hepatotoxicity to sodium valproate: a review. Gut 1984; 25: 673-81.
9. Doose H (für den Königsteiner Arbeitskreis für Epileptologie). Früherkennung von Komplikationen einer Valproattherapie im Kindesalter. Pädiatr Praxis 1986; 33: 581-2.
10. Loiseau P. Sodium valproate, platelet dysfunction, and bleeding. Epilepsia 1981; 22: 141-6.
11. Rochel M, Ehrenthal W. Effect of valproic acid on hepatic function. In: Oxley J, Janz D, Meinardi H, eds. Antiepileptic drugs, 3rd edn. New York: Raven Press, 1983; 241-55.
12. May RB, Sunder TR. Hematologic manifestations of long-term valproate therapy. Epilepsia 1993; 34: 1089-101.
13. Sussman NM, McLain W. A direct hepatotoxic effect of valproic acid. JAMA 1972; 242: 1173-4.
14. Sussman NM, McLain W, Leppik IE. Hepatotoxicity of valproic acid. Neurology 1979; 29: 601.
15. Voelzke E, Doose H. Dipropylacetate in the threatment of epilepsy. Epilepsia 1973; 14: 185-93.
16. Willmore LJ, Wilder BJ, Brani J. Effect of valproic acid on hepatic function. Neurology 1978; 28: 961-4.
17. Rochel M, Ehrenthal W. Haematological side effects of valproic acid. In: Oxley J, Janz D, Meinardi H. eds. Chronic toxicity of antiepileptic drugs. New York: Raven Press, 1983; 101-3.
18. Schneble H. Labor-Parameter unter Valproat-Therapie. Nervenarzt 1982; 53: 684-90.
19. Gadner H, Bensel J, Grimm B, Riehm M. Beeinflussung der Hämostase durch Dipropylessigsäure. Monatsschr Kinderheilk 1976; 124: 448-9.
20. Camfield C, Camfield P, Smith E, Tibbles JAR. Asymptomatic children with epilepsy: Little benefit from screening for anticonvulsant-induced liver, blood, or renal damage. Neurology 1986; 36: 838-41.